Epithalon at a glance
Epithalon is four amino acids long: Ala-Glu-Asp-Gly, hence the abbreviation AEDG; epitalon is a common alternative spelling. Its developers are Vladimir Khavinson and colleagues of the St Petersburg Institute of Bioregulation and Gerontology. That school had spent years on epithalamin, an extract prepared from the pineal glands of animals, and wanted a defined molecule to set beside it: an extract is a mixture, whereas a tetrapeptide can be synthesised, measured and compared between laboratories.
It is usually grouped with longevity compounds such as GHK-Cu. With BPC-157 it shares a weakness of the literature: most of what is published comes from one place.
- Ala-Glu-Asp-Gly, 390.3 Da; no receptor identified.
- Central claim: telomerase activity and longer telomeres in cultured human fibroblasts (2003).
- The main mouse study found mean lifespan unchanged.
- No randomised, placebo-controlled human trial of Epithalon itself.
How Epithalon works
What follows is the proposal of the St Petersburg school, not an established mechanism. The school calls peptides of this size bioregulators: very short chains that get into the cell, meet DNA or chromatin there and alter which genes are switched on. For Epithalon the gene that matters encodes the catalytic subunit of telomerase.
Telomeres are the repeat sequences that cap each chromosome end, and telomerase is the enzyme able to rebuild them. Body cells in humans mostly produce very little telomerase or none. Their telomeres get shorter at each division and eventually division stops, the limit that carries Leonard Hayflick’s name.
No receptor for the peptide is known, and the notion that four residues act directly on chromatin originates with the people who developed it. That is why the data panel reads “Telomerase (reported)”. The sources give no half-life.
The evidence ladder for Epithalon
| Evidence level | Model or trial | Main finding |
|---|---|---|
| Cell culture | Telomerase-negative human fetal fibroblasts; Khavinson, Bondarev and Butyugov, 2003 (Bulletin of Experimental Biology and Medicine) | Catalytic subunit expressed, enzyme activity detectable, telomeres longer |
| Cell culture | Human fetal lung fibroblasts; follow-up, 2004 | Controls stopped at passage 34; treated cultures made ten more divisions and were still dividing at passage 44 |
| Cell culture (outside group) | Human cell lines; Brunel University London, 2025 (Biogerontology) | Telomeres lengthened with dose: via telomerase in normal cells, via the alternative lengthening pathway in cancer lines |
| Animal study | Female SHR mice; Anisimov et al., 2003 (Biogerontology) | Mean lifespan unchanged; longest-lived tenth lived 13.3% longer; oestrous function lost more slowly; 17.1% fewer chromosome aberrations in bone marrow; less leukaemia; total tumour incidence unchanged |
| Human reports | St Petersburg school; mostly about the extracts epithalamin and thymalin, given to older patients | Not studies of Epithalon itself |
| Randomised trial | None found | – |
The mouse result is narrower than its reputation: the average mouse lived no longer. Anisimov’s institute, the Petrov Research Institute of Oncology, is likewise in St Petersburg, so the study belongs to the same circle as the cell work. The first confirmation from outside that circle is the 2025 paper, which had to be corrected shortly after publication because the wrong figures had been printed. Cite the corrected version.
Confirmation would mean telomere and telomerase read-outs repeated by unrelated groups, with standard assays, several human cell types and documented batch identity and purity. Then lifespan work in mice of both sexes and mixed genetic background, at several sites. Only after that, pre-registered trials in people with clinical end points.
Epithalon doses reported in studies
Reference values from the published record, listed to describe the studies and not as guidance.
| Setting | Dose | Schedule | Route | Note |
|---|---|---|---|---|
| Fetal fibroblast cultures (2003, 2004) | Concentration not given in the sources | – | In the culture medium | Telomerase read-outs; divisions counted by passage |
| Female SHR mice (2003) | 1.0 µg per mouse, about 30–40 µg/kg | 5 days every month, from 3 months old until natural death | Subcutaneous | 54 animals per group |
| Human cell lines (2025) | A range, to test dose dependence | – | In culture | Telomere length measured |
| Humans | None validated | – | – | No controlled human trial exists |
Only the mouse study states its dosing precisely. Its per-kilogram figure belongs to one strain of mouse and cannot be scaled to another species.
Safety findings and open questions
There is too little evidence to speak of a safety profile. Small studies reported no problems, which is a different statement. In their 2003 paper the mouse investigators judged prolonged intermittent dosing to be safe for the animals: one strain, one sex, one laboratory.
- Most human cancers have telomerase switched back on. Does a telomerase activator carry a tumour risk? Unresolved, and a reason for watchfulness.
- How far do mouse tumour data carry? Laboratory mice have much longer telomeres than humans and express telomerase in more tissues, so probably not far.
- How often do adverse effects occur in people? No controlled trial has collected safety data systematically.
Bench notes: storing and reconstituting Epithalon
The data panel specifies −20 °C for the powder. Keep the vial closed and dry until use, and allow it to reach room temperature before the seal is broken, so that no condensation forms inside.
Bacteriostatic water is the customary solvent in research settings because its preservative lets one vial be sampled more than once. Add it along the vial wall and swirl; do not shake. Solutions are much less stable than powder, so keep them refrigerated and freeze single-use aliquots for longer work. Batch identity is a weak point of this literature, so record the lot number in the lab notebook. The general procedure is in Storage and Reconstitution: A Bench Protocol.
Status in the Netherlands, Belgium and Luxembourg
No EU marketing authorisation exists for Epithalon; such authorisations come from the European Medicines Agency and would apply equally in the Netherlands, Belgium and Luxembourg. EU medicines law treats a product as medicinal when it is presented as a treatment or prevention for disease, or when it serves to modify physiological functions by pharmacological action; it must then be authorised before it is sold for human use. Epithalon is therefore on the European market as a research chemical only. National and institutional rules on possession and import differ. The line between a medicine and research material is drawn in Research Peptides Explained: From Amino Acid to Assay.
The WADA Prohibited List does not name Epithalon. That is not a clearance: class S0 covers any pharmacological substance with no current approval for human therapeutic use. Athletes should confirm the position with their anti-doping organisation.
Ordering Epithalon for research in the Benelux
King Peptides does not list Epithalon. The closest product in its range is GHK-Cu 100 mg, close only in that both belong to longevity research. It is a different compound, described in the GHK-Cu profile: a tripeptide that binds copper, with a literature on collagen and wound repair, so it is no substitute in a telomere experiment.
Certificate checks are the same for any peptide and any supplier: a lot number that matches the vial, an HPLC purity figure, and a mass spectrum that fits the molecule. For Epithalon the expected mass is 390.3 Da. GHK-Cu from King Peptides is listed at 98% or higher on HPLC, with 340.4 Da for the free peptide or about 402 Da for the copper complex, and the shop provides a lot-specific certificate with HPLC and mass spectrometry for every lot. Checking a Certificate of Analysis, Line by Line shows where to find each value.
Shop orders are dispatched from the Netherlands in a tracked parcel, usually arriving within 1–2 business days in the Netherlands and 3–5 business days in Belgium and Luxembourg, without customs clearance inside the EU. The supplier checklist is in Buying Research Peptides in the Netherlands, Belgium and Luxembourg.
Epithalon: quick answers
Can results with epithalamin be applied to Epithalon? No. Epithalamin is a pineal extract holding many peptides, Epithalon one synthetic tetrapeptide. Findings do not carry over.
Did Epithalon make mice live longer? Not on average. In the 2003 study mean lifespan was unchanged; only the longest-lived tenth of the animals lived 13.3% longer.
Has telomere lengthening been shown in people? No. Cultured human cells are as far as the reports go; the 2025 paper added a laboratory from outside the founding school. Nobody has measured it in a controlled human trial.
Why does a single research school matter so much? One group tends to share methods, reagents and assumptions. Only repetition elsewhere can show that an effect is real, and for Epithalon that has barely begun.
Research use only. This page describes Epithalon for laboratory and scientific research. Research material has no marketing authorisation, whatever the status of the molecule as a medicine elsewhere, and is not meant for human or veterinary use. Nothing on this page is medical advice; the doses above are those reported in published studies, not recommendations. Check the rules that apply in your country and at your institution before ordering.